Top

Published in:

01-07-2009 | SSAT Controversy in GI Surgery Debate

Endotherapy for Barrett’s Esophagus with High-Grade Dysplasia and Intramucosal Carcinoma

Author: Drew B. Schembre

Published in: Journal of Gastrointestinal Surgery | Issue 7/2009

Excerpt

The incidence of adenocarcinoma of the esophagus in the USA appears to be rising rapidly.1,2 The prevalence of Barrett’s esophagus (BE) appears to be increasing as well.3 The vast majority of adenocarcinoma of the esophagus arises within Barrett’s esophagus, and the identification of the immediate histologic precursor to cancer, high-grade dysplasia (HGD), is the endpoint of current Barrett’s surveillance programs.4 Once HGD has been found, management has included close endoscopic surveillance, esophagectomy, and, more recently, endoscopic ablative therapies (ET). ET has included photodynamic therapy (PDT), endoscopic mucosal resection (EMR), endoscopic submucosal dissection, radiofrequency ablation (RFA) and cryotherapy, as well as a variety of thermal treatments such as argon plasma coagulation (APC).5‐9 …

National Cancer Institute website. http://www.cancer.gov, 2003.

Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47.PubMedCrossRef

Van Soest EM, Dieleman JP, Siersema PD et al. Increasing incidence of Barrett’s oesophagus in the general population. Gut 2008;54:1062–1066. doi:10.1136/gut.2004.063685.CrossRef

Williamson WA, Ellis FH, Gibbs SP et al. Barrett’s esophagus: Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212–2216. doi:10.1001/archinte.151.11.2212.PubMedCrossRef

Overholt BF, Lightdale CJ, Wang KK, Canto MI et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett’s esophagus: International, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488–498. doi:10.1016/j.gie.2005.06.047.PubMedCrossRef

Sharma VK, Fleischer DE, Wang KK et al. A randomized multi-center trial of radiofrequency (RF) ablation of specialized intestinal metaplasia (SIM) of the esophagus using a balloon-based bipolar electrode array: Preliminary results. Gastrointest Endosc 2004;59:113. doi:10.1016/S0016-5107(04)00554-1.CrossRef

Jung KW, Lee OJ. Extensive spontaneous submucosal dissection of the esophagus: Long-term sequential endoscopic observation and treatment. Gastrointest Endosc 2002;55:262–265. doi:10.1067/mge.2002.121872.PubMedCrossRef

Johnston MH. Cryotherapy and other newer techniques. Gastrointest Endosc Clin N Am. 2003;13:491–504. doi:10.1016/S1052-5157(03)00044-8, (Review. 22 refs. Journal Article. Review).PubMedCrossRef

Dulai GS, Jensen DM, Cortina G et al. Randomized trial of argon plasma coagulation vs, multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 2005;61:232–240. doi:10.1016/S0016-5107(04)02576-3.PubMedCrossRef

10.

Falk GW, Rice TW, Goldblum JR, Richter JE. Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc 1999;49:170. doi:10.1016/S0016-5107(99)70482-7.PubMedCrossRef

11.

Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett’s esophagus. Gastrointest Endosc Clin N Am. 2003;13:369. doi:10.1016/S1052-5157(03)00006-0.PubMedCrossRef

12.

Sampliner R, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002;97:1888–1895. doi:10.1111/j.1572-0241.2002.05910.x.PubMedCrossRef

13.

Boolchand V, Faulx A, Das A et al. Primary care physician attitudes toward endoscopic screening for GERD symptoms and unsedated esophagoscopy. Gastrointest Endosc 2006;63:228–233. doi:10.1016/j.gie.2005.06.044.PubMedCrossRef

14.

Lin O, Schembre D, Mergener K et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett’s esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc 2007;65:577–583. doi:10.1016/j.gie.2006.06.035.PubMedCrossRef

15.

Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–831. doi:10.1056/NEJM199903183401101.PubMedCrossRef

16.

Liu L, Hofstetter WL, Rashid A et al. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. Am J Surg Pathol 2005;29:1079–1085.PubMed

17.

Rice TW, Zuccaro G, Adelstein DJ et al. Esophageal carcinoma: Depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998;65:787–792. doi:10.1016/S0003-4975(97)01387-8.PubMedCrossRef

18.

Buskens C, Westerterp M, Lagarde S et al. Prediction of appropriateness of local endoscopic treatment for high-grade dysplasia and early adenocarcinoma by EUS and histopathologic features. Gastrointest Endosc 2004;60:703–710. doi:10.1016/S0016-5107(04)02017-6.PubMedCrossRef

19.

Berenson MM, Johnson TD, Markowitz NR et al. Restoration of squamous mucosa after ablation of Barerett’s esophageal epithelium. Gastroenterology 1993;104:1686–1691.PubMed

20.

Sampliner RE, Hixon LJ, Fennerty MB et al. Regression of Barrett’s esophagus by laser ablation in an anacid environment. Dig Dis Sci. 1993;38:365–8. doi:10.1007/BF01307557.PubMedCrossRef

21.

Schembre D, Ayub K, Jiranek G. Endoscopic mucosal resection changes staging for early-stage neoplasia in Barrett’s esophagus compared to pinch biopsies and EUS. Gastrointest Endosc 2006;63:AB122.CrossRef

22.

Larghi A, Lightdale C, Memeo L et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett’s esophagus. Gastrointest Endosc 2005;62:16–23. doi:10.1016/S0016-5107(05)00319-6.PubMedCrossRef

23.

Peters FP, Kara MA, Rosmolen WD et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett’s esophagus with early neoplasia: A prospective study. Am J Gastroenterol 2006;101:1449–1457. doi:10.1111/j.1572-0241.2006.00635.x.PubMedCrossRef

24.

Wolfsen HC. Present status of photodynamic therapy for high-grade dysplasia in Barrett’s esophagus. J Clin Gastroenterol 2005;39:189–202. doi:10.1097/01.mcg.0000152748.56902.02.PubMedCrossRef

25.

Buttar NS, Wang KK, Lutzke LS et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett’s esophagus. Gastrointest Endosc 2001;54:682–688.PubMed

26.

Pacifico RJ, Wang KK, Wongkeesong LM, Buttar NS, Lutzke LS. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett’s esophagus. Clin Gastroenterol Hepatol 2003;1:252–257. doi:10.1016/S1542-3565(03)00129-0.PubMedCrossRef

27.

Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc 2003;58:183–188. doi:10.1067/mge.2003.327.PubMedCrossRef

28.

Ell C, May O, Pech L et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc 2007;65:3–10. doi:10.1016/j.gie.2006.04.033.PubMedCrossRef

29.

Schembre DB, Huang JL, Lin OS et al. Treatment of Barrett’s esophagus with early neoplasia: A comparison of endoscopic therapy and esophagectomy. Gastrointest Endosc 2008;67:595–601. doi:10.1016/j.gie.2007.08.042.PubMedCrossRef

30.

Ganz RA, Overholt BF, Sharma VK et al. Circumferential ablation of Barrett’s esophagus that contains high-grade dysplasia: A U.S. multicenter registry. Gastrointest Endosc 2008;68:35–40.PubMedCrossRef

31.

Pouw RE, Sondermeijer C, Ten Kate FJ et al. Stepwise circumferential and focal radiofrequency energy ablation of Barrett’s esophagus with early neoplasia: First European multi-centre trial. Gastrointest Endosc 2008;76:AB137. doi:10.1016/j.gie.2008.03.255.CrossRef

32.

Dumont JA, Vargo JJ, Zuccaro G et al. Results of cryospray ablation for esophageal high grade dysplasia (HGD) and intramucosal cancer (IMCA) in high risk non-surgical patients. Gastrointest Endosc 2008;67:AB176. doi:10.1016/j.gie.2008.03.418.CrossRef

33.

Prasad G, Wang K, Buttar N et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus. Gastroenterol. 2007;132:1226–1233. doi:10.1053/j.gastro.2007.02.017.CrossRef

34.

Birkmeyer JD et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346(15):1128–1137. doi:10.1056/NEJMsa012337.PubMedCrossRef

35.

Hendrick JR, Nichols FC, Miller DM et al. High-grade esophageal dysplasia: Long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73:1697–703. doi:10.1016/S0003-4975(02)03496-3.CrossRef

36.

Moraca RJ, Low DE. Outcomes and health-related quality of life after esophagectomy for high-grade dysplasia and intra-mucosal cancer. Arch Surg 2006;141:545–551. doi:10.1001/archsurg.141.6.545.PubMedCrossRef

37.

Schembre D, Arai AD, Levy SM et al. Quality of life after esophagectomy and endoscopic therapy for Barrett’s esophagus with high-grade dysplasia or intra-mucosal carcinoma. Gastrointest Endosc 2008;67:AB251. doi:10.1016/j.gie.2008.03.668.CrossRef

38.

Gossner L, Stolte M, Sroka R et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-amino leuvulinic acid. Gastroenterol. 1998;114:448–455. doi:10.1016/S0016-5085(98)70527-X.CrossRef

39.

Konda V, Ross A, Ferguson M et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett’s esophagus overestimated? Clin Gastroenterol Hepatol 2008;6:159–164. doi:10.1016/j.cgh.2007.09.013.PubMedCrossRef

40.

Feith M, Stein HJ, Siewert JR. Pattern of lymphatic spread of Barrett’s cancer. World J Surg 2003;27:1052–1057. doi:10.1007/s00268-003-7060-2.PubMedCrossRef

41.

Mino-Kenudson M, Brugge WR, Puricelli WP et al. Management of superficial Barrett’s epithelium-related neoplasms by endoscopic mucosal resection: Clinicopathologic analysis of 27 cases. Am J Surg Pathol 2005;29:680–686. doi:10.1097/01.pas.0000154129.87219.fa.PubMedCrossRef

42.

Van Laethem JL, Jagodzinski R, Peny MO et al. Argon plasma coagulation in the treatment of Barrett’s high-grade dysplasia and in situ adenocarcinoma. Endoscopy 2001;33:257–261. doi:10.1055/s-2001-12803.PubMedCrossRef

43.

Peters F, Kara M, Rosmolen W et al. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett’s esophagus after endoscopic resection. Endoscopy 2005;37:418–424. doi:10.1055/s-2005-861198.PubMedCrossRef

44.

Pech O, Gossner L, May A et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005;62:24–30. doi:10.1016/S0016-5107(05)00333-0.PubMedCrossRef

45.

Sharma VK, Wang K, Overholt B et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007;65:185–195. doi:10.1016/j.gie.2006.09.033.PubMedCrossRef

46.

Ross A, Noffsinger A, Dye C et al. High prevalence of buried glands in mucosectomy specimens from patients with Barrett’s esophagus and high grade dysplasia or intramucosal carcinoma: implications for treatment and surveillance. Gastrointest Endosc 2007;65:AB137. doi:10.1016/j.gie.2007.03.160.CrossRef

47.

Hornick JL, Blount PL, Sanchez CA et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett’s esophagus. Am J Surg Pathol 2005;29:372–380. doi:10.1097/01.pas.0000147403.33509.de.PubMedCrossRef

48.

Franchimont D, Covas A, Brasseur C et al. Newly developed Barrett’s esophagus after subtotal esophagectomy. Endoscopy 2003;35:850–853. doi:10.1055/s-2003-42623.PubMedCrossRef

49.

Wolfsen HC, Hemminger LL, DeVault K. Recurrent Barrett’s esophagus and adenocarcinoma after esophagectomy. BMC Gastroenterol 2004;4:1–5. doi:10.1186/1471-230X-4-18.CrossRef

50.

Badreddine RJ, Wang KK, Prasad GA et al. Does endoscopic mucosal resection (EMR) affect subsequent esophagectomy? Gastrointest Endosc 2008;67:AB94.

51.

Overholt BF, Wang KK, Burdick JJ et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc 2007;66:460–468.

52.

Gondrie JJ, Pouw RE, Sondermeijer CM et al. Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008;40:370–379.

53.

Greenwald BD, Horwhat JD, Abrams JA et al. Endoscopic cryotherapy ablation is safe and well-tolerated in Barrett’s esophagus, esophageal dysplasia and esophageal cancer. Gastrointest Endosc 2008;67:AB76.

54.

Heitmiller RF, Redmond M, Hamilton SR. Barrett’s esophagus with high-grade dysplasia: An indication for prophylactic esophagectomy. Ann Surg 1996;224:66–71. doi:10.1097/00000658-199607000-00010.PubMedCrossRef

55.

Zaninotto G, Parenti AR, Ruol A et al. Oesophageal resection for high-grade dysplasia in Barrett’s oesophagus. Br J Surg 2000;87:1102–1105. doi:10.1046/j.1365-2168.2000.01470.x.PubMedCrossRef

56.

Headrick JR, Nichols FC III, Miller DL et al. High-grade esophageal dysplasia: Long-term survival and quality of life after esophagectomy. Ann Thorac Surg 2002;73:1697–703. doi:10.1016/S0003-4975(02)03496-3.PubMedCrossRef

57.

Luketich JD, Alvelo-Rivera M, Buenaventura PO et al. Minimally invasive esophagectomy: Outcomes in 222 patients. Ann Surg 2003;238:486–495.PubMed

58.

Tseng EE, Wu TT, Yeo CJ, Heitmiller RF. Barrett’s esophagus with high grade dysplasia: Surgical results and long-term outcome—An update. J Gastrointest Surg 2003;7:164–167. doi:10.1016/S1091-255X(02)00153-1.PubMedCrossRef

59.

Williams VA, Watson TJ, Herbella FA et al. Esophagectomy for high-grade dysplasia is safe, curative and results in good alimentary outcome. J Gastrointest Surg 2007;11:1589–1597. doi:10.1007/s11605-007-0330-9.PubMedCrossRef

Title: Endotherapy for Barrett’s Esophagus with High-Grade Dysplasia and Intramucosal Carcinoma
Author: Drew B. Schembre
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 7/2009
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-009-0862-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Endotherapy for Barrett’s Esophagus with High-Grade Dysplasia and Intramucosal Carcinoma

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2009

High Jejunal Perforation Complicating Tuberculous Abdominal Cocoon: A Rare Presentation in Immune-Competent Male Patient

Quality of Life After Ileoanal Pouch: A Comparison of J and W Pouches

Glyceryl Trinitrate Ointment (0.25%) and Anal Cryothermal Dilators in the Treatment of Chronic Anal Fissures

Pancreaticojejunostomy with Applicationof Fibrinogen/Thrombin-Coated Collagen Patch (TachoSil®) in Roux-en-Y Reconstruction after Pancreaticoduodenectomy

National Trends and Outcomes for the Surgical Therapy of Ileocolonic Crohn’s Disease: A Population-Based Analysis of Laparoscopic vs. Open Approaches

A Simple Scoring System Based on Clinical Features to Predict Locally Advanced Rectal Cancers